AAAlaa Abdrabou Abouelmagd

Alaa Abdrabou Abouelmagd

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alaa Abdrabou Abouelmagd has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Left Atrial Appendage Occlusion vs Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: A Meta‐Analysis

    by Ahmed Nazmy, Alaa Abdrabou Abouelmagd, Ahmed Sobhy, Mennatullah Ashour, Hassan El‐Shirbiny, Moneeb Khalaph, Ahmed Yasser Shaban, Mahmoud Nazmy, Amroos Shabaan, Abdullah Farahat Elbanna, et al.

    Background: Left atrial appendage occlusion (LAAO) has emerged as a non‐pharmacological alternative to oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation (AF). Following the publication of recent CHAMPION‐AF and CLOSURE‐AF trials, an updated synthesis of evidence is warranted to clarify the long‐term comparative efficacy and safety of LAAO versus OAC in patients with AF. Methods: We conducted a systematic review and meta‐analysis of randomized controlled trials (RCTs) comparing LAAO with OAC in adults with AF. A comprehensive search of major databases was performed from inception to April 2026. The primary efficacy outcomes were major adverse cardiovascular events (MACE) and stroke. The primary safety outcome was non–procedure‐related bleeding. Random‐effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Results: Six RCTs including 7,004 patients (3,681 LAAO; 3,323 OAC) were analyzed. No statistically significant difference was observed for MACE (7.5% vs 6.9%; RR 1.03, 95% CI 0.79‐1.34) or stroke (3.7% vs 3.2%; RR 1.07, 95% CI 0.80‐1.43). LAAO was associated with a significantly lower risk of non‐procedure‐related bleeding (9.8% vs 16.7%; RR 0.63, 95% CI 0.52‐0.77), corresponding to an absolute risk reduction of 6.9% and an approximate number needed to treat of 15 based on crude pooled event rates over the observed trial follow‐up. Trial sequential analysis indicated that the accumulated evidence for MACE and stroke remained inconclusive. Comparator‐type subgroup analyses showed no significant interaction for MACE ( p = 0.67) or stroke ( p = 0.81) between contemporary predominantly‐DOAC and VKA comparator trials. Conclusions: LAAO was associated with lower non‐procedure‐related bleeding, while no statistically significant differences were observed for MACE or stroke. The available efficacy evidence remains inconclusive regarding equivalence or non‐inferiority, and larger trials are needed. These findings support individualized consideration of LAAO when the long‐term bleeding burden of anticoagulation is clinically important.

  • Open Access

    Mechanical Circulatory Support During Ventricular Tachycardia Ablation: A Systematic Review and Meta‐Analysis of Procedural and Clinical Outcomes

    by Ahmed Nazmy, Hassan El‐Shirbiny, Alaa Abdrabou Abouelmagd, Noha Hammad, Samar Mohamed Sadek, Ahmed Wahdan Kasem, Ahmed Elazab, Reda Biomy, Islam Saboukh, Mohamed Kamal Salama, et al.

    Catheter ablation is an established therapy for ventricular tachycardia (VT); however, hemodynamic instability frequently limits procedural mapping and success. Temporary mechanical circulatory support (tMCS) devices are increasingly used to maintain end‐organ perfusion during VT ablation, yet their impact on clinical outcomes remains uncertain. We aimed to evaluate the impact of tMCS on clinical outcomes and periprocedural complications in patients undergoing VT ablation. A systematic search of PubMed/MEDLINE, Scopus, Web of Science, and Cochrane CENTRAL was conducted from database inception through December 2025. We included observational studies enrolling adult patients undergoing VT ablation with tMCS, compared with VT ablation performed without MCS. Primary outcomes were all‐cause mortality, in‐hospital mortality, procedural success, VT recurrence, and major adverse cardiovascular events (MACE). Ten observational studies comprising 16,838 patients were included, of whom 1402 received tMCS. There was no significant difference in all‐cause mortality between tMCS and no‐MCS groups (RR 1.71, 95% CI 0.68 to 4.26), procedural success (RR 1.05, 95% CI 0.92 to 1.21), VT recurrence (RR 0.99, 95% CI 0.80 to 1.22), or MACE (RR = 0.79, 95% CI: 0.62 to 1.01). However, tMCS use was associated with significantly higher in‐hospital mortality (RR 7.41, 95% CI 4.77 to 11.66). The tMCS group also demonstrated increased risks of stroke, pericardial effusion or tamponade, and periprocedural complications. In non‐randomized studies, tMCS during VT ablation was not associated with improved long‐term outcomes, while higher in‐hospital mortality and complications likely reflected patient selection and timing of support rather than adverse device effects.

  • Efficacy and Safety of Risankizumab in Crohn’s Disease: A Systematic Review and Meta-Analysis of Randomized Trials and Real-World Evidence

    by Alaa Abdrabou Abouelmagd, Mazen Negmeldin Yassin, Dina Essam Abo-Elnour, Menna M. Aboelkhier, Nada G. Hamam, Abdelrahman A. Elareef, Mohamed Saad Sayed, Mazen Ibrahem Gado, Talaat M. Elqadi, Ahmed Elazab, et al.

    Crohn's disease (CD) management remains challenging, particularly in patients refractory to multiple biologics. Risankizumab (RZB), a selective IL-23 p19 inhibitor, has recently been approved for CD. We performed a systematic review and meta-analysis to assess the efficacy and safety of RZB in moderate-to-severe CD using both randomized controlled trials (RCTs) and real-world evidence (RWE). We searched PubMed, Scopus, Web of Science, and Embase from inception to April 2025. We included RCTs comparing RZB with placebo and observational studies evaluating RZB in CD. Primary endpoints were clinical remission at induction and maintenance. Secondary endpoints included endoscopic remission and safety outcomes. This study was registered with PROSPERO (CRD420251030978). Five RCTs and nine observational studies (n = 3275) were included. In RCTs, RZB significantly increased clinical remission rates at induction (RR: 1.90, 95% CI [1.63; 2.20]) and maintenance (RR: 1.34, 95% CI [1.15; 1.55]) compared with placebo. Endoscopic remission was also significantly higher with RZB compared to placebo at induction (RR: 3.25, 95% CI [2.43; 4.35]) and maintenance (RR: 2.04, 95% CI [1.22; 3.42]). Pooled RWE demonstrated clinical remission rates of 57% at 12 weeks and 44% at 1 year. Subgroup analyses confirmed efficacy in patients with prior ustekinumab failure. No increased risk of serious adverse events was observed. Risankizumab demonstrates robust efficacy in inducing and maintaining clinical and endoscopic remission in moderate-to-severe CD. Real-world data confirm its sustained effectiveness and favorable safety profile in refractory populations (defined as patients with prior failure of one or more biologics or advanced therapies), supporting its positioning in the therapeutic landscape.

  • Jailed CIED Leads After TTVR

    by Alaa Abdrabou Abouelmagd, Gregg W. Stone

  • Open Access

    Effect of Early Versus Late Catheter‐Directed Intervention on Clinical Outcomes in Acute Pulmonary Embolism: A Systematic Review and Meta‐Analysis

    by Alaa Abdrabou Abouelmagd, Bahy Abofrekha, Bashar M. Al Zoubi, Ibrahim Gowaily, Mohamed Hassan Mady, Anas Hussein Heiba, AlMothana Manasrah, Mohamed Elshahat, Mustafa Turkmani, Mohamed Abuelazm

    Catheter‐directed intervention (CDI) in patients presenting with pulmonary embolism (PE) is suggested to improve in‐hospital outcomes. We aimed to compare the effect of early versus late initiation of CDI on in‐hospital outcomes. A systematic review and meta‐analysis were conducted according to PRISMA guidelines. A comprehensive search of PubMed, Scopus, Web of Science, and Embase databases was performed from inception to May 2025. Data extraction was conducted independently by multiple reviewers. Statistical analysis was performed using R software version 4.3.2, and odds ratio (OR) and mean difference (MD) with 95% confidence intervals (CIs) were combined using a random‐effects model. Six studies, including 53,472 patients, were included. Early intervention before 24 h significantly reduced mortality (OR 0.61, 95% CI [0.44–0.84]; I ² = 0%). Moreover, Early intervention before 24 h significantly reduced the all‐cause readmission in patients with acute PE (OR = 0.81 (95% CI: [0.73, 0.89]; I² = 0%). There was no significant difference in risk of major bleeding in early vs late intervention (OR = 0.82; 95% CI: [0.48, 1.39]; I² = 69.3%). Also, early intervention before 24 h significantly reduced the length of hospital stay (LOS) (MD = –3.11 days (95% CI: [–4.33, –1.89]; I ² = 0%). This meta‐analysis showed that early CDI, particularly within 24 h of presentation, is associated with a significant reduction in both mortality and all‐cause readmission in patients with acute PE, without increasing the risk of bleeding. These findings support the concept of “time‐is‐myocardium” and reinforce the need for structured protocols that enable early therapeutic intervention. Further randomized controlled trials are needed to confirm these findings and to establish the optimal timing for this potentially life‐saving therapy.


  • Open Access

    Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis

    by Alaa Abdrabou Abouelmagd, Shrouk Ramadan, Mohamed Saad Sayed, Omar Abdulrahman Saad, Mazen Negmeldin Yassin, Alaa Mohammed Mostafa, Kerollos Abdelsayed

    Lorundrostat, a novel selective aldosterone synthase inhibitor, has emerged as a potential treatment for uncontrolled hypertension. However, a comprehensive summary of its efficacy and safety profile is currently lacking. This meta-analysis aims to synthesize evidence from published randomized controlled trials (RCTs) to evaluate the clinical benefits and risks of lorundrostat in this patient population. Following the PRISMA guidelines, a systematic search was conducted on PubMed, Scopus, and Web of Science for RCTs comparing lorundrostat with placebo. The primary outcomes were changes from baseline in systolic and diastolic blood pressure. Data were pooled using a random-effects model to calculate mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes, with corresponding 95% confidence intervals (CIs). Three RCTs comprising 1568 patients were included. Compared to placebo, lorundrostat significantly reduced both 24-h systolic blood pressure (MD: − 6.65 mmHg; 95% CI: [− 9.95 to − 3.35]) and office systolic blood pressure (MD: − 7.94 mmHg; 95% CI: [− 9.72 to − 6.15]). While the risk of serious adverse events was comparable, lorundrostat was associated with a higher incidence of hyperkalemia (RR: 5.47; 95% CI: [1.55 to 19.36]) and hyponatremia (RR: 1.95; 95% CI: [1.13 to 3.36]). Notably, lorundrostat significantly reduced the risk of adrenal insufficiency (RR: 0.15; 95% CI: [0.03 to 0.91]). Lorundrostat may be an effective agent for lowering blood pressure in patients with uncontrolled hypertension. Its safety profile is acceptable but requires careful monitoring of serum electrolytes and renal function. The reduced risk of adrenal insufficiency highlights its selectivity and potential as a valuable therapeutic option. Further large-scale, long-term studies are needed to confirm its sustained benefits and safety.


  • Semaglutide and MASH resolution: A pooled analysis of recent trials

    by Alaa Abdrabou Abouelmagd, Ahmed Elazab, Mohamed Diaa Gabra, Hazem Abosheaishaa


  • Open Access

    Hyponatremia-Induced Rhabdomyolysis in a Patient with Psychogenic Polydipsia: A Case Report

    by Hazem Abosheaishaa, Toka Amin, Philip Mendy, Omar Abdelhalim, Alaa Abdrabou Abouelmagd, Ahmed Hassan

    Hyponatremia is a common electrolyte abnormality that can lead to various complications, including rhabdomyolysis. Observational studies have identified a correlation between hyponatremia and the occurrence of rhabdomyolysis in hospitalized patients. We report a 45-year-old male with a medical history of hypertension, hyperlipidemia, and a congenital neurological defect featuring an 8 cm right frontal porencephalic cyst communicating with the right lateral ventricle, colpocephaly, congenital left hemiparesis, paranoid schizophrenia, anxiety, and depression. He presented with rhabdomyolysis caused by hyponatremia and aggravated by psychogenic polydipsia. A hyponatremic state caused by psychogenic polydipsia may induce rhabdomyolysis in patients with a genetic predisposition. Hence, monitoring muscle markers in these patients is crucial, with further evidence needed to establish hyponatremia as the primary cause of rhabdomyolysis in the absence of other confounders.

  • Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials

    by Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir, Fares Abdelsalam, Ahmed Marey, Yousef Tanas, Duha Milad Abuklish, Mohamed Mohamed Belal

    Retatrutide is a novel triple agonist targeting the receptors of glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon. We sought to assess the efficacy and safety of retatrutide in obese patients with or without diabetes. PubMed, Scopus, Web of Science, and Cochrane databases were searched from inception until May 2024. Eligible studies comprised randomized controlled trials that compared retatrutide with placebo in obese patients. We excluded studies on healthy populations, non-English texts, single-arm studies, animal studies, and abstracts. RevMan software (version 5.4) was used for analysis, with subgroup evaluation by dose (4 mg, 8 mg, 12 mg). Three randomized controlled trials, encompassing 878 patients, satisfied our inclusion criteria. Retatrutide significantly reduced body weight (mean difference [MD]: −14.33%), body mass index (MD: −5.38), waist circumference (MD: −10.51 cm), fasting plasma glucose (MD: −23.51 mg/dL), hemoglobin A1c (MD: −0.91%), and systolic and diastolic blood pressure (MD: −9.88 mm Hg and −3.88 mm Hg, respectively), all with P values < 0.00001. No significant difference in adverse events was observed between the groups (relative risk: 1.11, P = 0.24). Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile. However, additional large and long-term trials are required to establish these results.